JP2023534300A - 癌の処置のための組成物および方法 - Google Patents

癌の処置のための組成物および方法 Download PDF

Info

Publication number
JP2023534300A
JP2023534300A JP2023503154A JP2023503154A JP2023534300A JP 2023534300 A JP2023534300 A JP 2023534300A JP 2023503154 A JP2023503154 A JP 2023503154A JP 2023503154 A JP2023503154 A JP 2023503154A JP 2023534300 A JP2023534300 A JP 2023534300A
Authority
JP
Japan
Prior art keywords
melittin
cancer
fusion peptide
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534300A5 (https=
Inventor
ピラール ブランカフォート，
シアラ ダッフィー，
Original Assignee
ジ ユニバーシティ オブ ウェスタン オーストラリア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902478A external-priority patent/AU2020902478A0/en
Application filed by ジ ユニバーシティ オブ ウェスタン オーストラリア filed Critical ジ ユニバーシティ オブ ウェスタン オーストラリア
Publication of JP2023534300A publication Critical patent/JP2023534300A/ja
Publication of JP2023534300A5 publication Critical patent/JP2023534300A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Insects & Arthropods (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2023503154A 2020-07-17 2021-07-16 癌の処置のための組成物および方法 Pending JP2023534300A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902478A AU2020902478A0 (en) 2020-07-17 Compositions and methods for the treatment of cancer
AU2020902478 2020-07-17
PCT/AU2021/050770 WO2022011434A1 (en) 2020-07-17 2021-07-16 Compositions and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023534300A true JP2023534300A (ja) 2023-08-08
JP2023534300A5 JP2023534300A5 (https=) 2024-07-30

Family

ID=79555877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503154A Pending JP2023534300A (ja) 2020-07-17 2021-07-16 癌の処置のための組成物および方法

Country Status (6)

Country Link
US (1) US20240391964A1 (https=)
EP (1) EP4182334A4 (https=)
JP (1) JP2023534300A (https=)
AU (1) AU2021309132A1 (https=)
CA (1) CA3189545A1 (https=)
WO (1) WO2022011434A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025178414A1 (ko) * 2024-02-22 2025-08-28 (주)에스엔이바이오 막관통 도메인을 포함하는 약물 전달체 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000318A1 (en) * 1990-06-25 1992-01-09 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods for preparation and uses thereof
JP2009510166A (ja) * 2005-10-04 2009-03-12 グリーンビル ホスピタル システム 潜伏性プロサイトトキシンおよびそれらの用途
CN101481422A (zh) * 2009-02-09 2009-07-15 孙妙囡 一种具有释药开关的抗肿瘤靶向融合蛋白及其应用
WO2015198072A1 (en) * 2014-06-27 2015-12-30 Stealthyx Therapeutics Limited Modified latency associated protein construct
CN103755813B (zh) * 2014-01-07 2016-08-10 中国人民解放军第二军医大学 一种靶向性抗肿瘤融合蛋白及其编码基因与表达质粒
CN109439686A (zh) * 2018-11-23 2019-03-08 天津农学院 一种重组减毒沙门氏菌lh430及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2445515T3 (en) * 2009-06-26 2016-07-04 Univ Leuven Kath antimicrobial agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000318A1 (en) * 1990-06-25 1992-01-09 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods for preparation and uses thereof
JP2009510166A (ja) * 2005-10-04 2009-03-12 グリーンビル ホスピタル システム 潜伏性プロサイトトキシンおよびそれらの用途
CN101481422A (zh) * 2009-02-09 2009-07-15 孙妙囡 一种具有释药开关的抗肿瘤靶向融合蛋白及其应用
CN103755813B (zh) * 2014-01-07 2016-08-10 中国人民解放军第二军医大学 一种靶向性抗肿瘤融合蛋白及其编码基因与表达质粒
WO2015198072A1 (en) * 2014-06-27 2015-12-30 Stealthyx Therapeutics Limited Modified latency associated protein construct
CN109439686A (zh) * 2018-11-23 2019-03-08 天津农学院 一种重组减毒沙门氏菌lh430及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAO JIE ET AL.: "RGD-modified lipid disks as drug carriers for tumor targeted drug delivery", NANOSCALE, vol. 8, JPN6025028820, 2016, pages 7209 - 7216, ISSN: 0005800095 *
SUN DEJUN ET AL.: "The Anti-Cancer Potency and Mechanism of a Novel Tumor-Activated Fused Toxin, DLM", TOXINS, vol. 7, JPN6025028819, 4 February 2015 (2015-02-04), pages 423 - 438, ISSN: 0005800096 *

Also Published As

Publication number Publication date
AU2021309132A1 (en) 2023-02-23
WO2022011434A1 (en) 2022-01-20
US20240391964A1 (en) 2024-11-28
EP4182334A4 (en) 2024-10-16
CA3189545A1 (en) 2022-01-20
EP4182334A1 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
Shin et al. Curvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy
Russell et al. Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer
ES2575508T3 (es) CAFs de duocarmicina que presentan una mejora en la actividad antitumoral in vivo
Seshacharyulu et al. Targeting EGF-receptor (s)-STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer
ES2742079T3 (es) Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4
EP3579860B1 (en) TRAILshort ANTIBODY AND METHODS OF USE
US20220249621A1 (en) TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS
Singh et al. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models
KR20230058442A (ko) 간세포성 암종에 대한 lag-3 길항제 요법
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
ES3009674T3 (en) Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
Luo et al. Genetically engineered biomimetic nanoparticles for synergistic activation of glioma-associated macrophages against glioblastoma
Brincks et al. Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma
Shu et al. The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma
Mehta et al. Disruptin, a cell-penetrating peptide degrader of EGFR: Cell-Penetrating Peptide in Cancer Therapy
JP2023534300A (ja) 癌の処置のための組成物および方法
WO2020081528A1 (en) Method and system for treating cancer utilizing tinagl 1
WO2022192372A1 (en) Methods and compositions for tusc2 combination therapy with pdk1 inhibition
ES2433840T3 (es) Anticuerpos para el tratamiento del cáncer
Sun et al. A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis
Rippo et al. Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies
WO2014164394A1 (en) Combination anti-her2 cancer therapy using muc1 peptides and chemotherapeutics
CA3199012A1 (en) Method of sensitizing cancers to immunotherapy using immunomodulatory agents
US20190255146A1 (en) Polypeptides for improved response to anti-cancer therapy
AU2024351102A1 (en) Treatment of cancers associated with beta-catenin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260220